Literature DB >> 18996025

Appraisal of immune response in lymphoproliferative syndromes: a systematic review.

Tomás Alvaro1, Marylène Lejeune, Patricia Escrivá, Lluís E Pons, Ramón Bosch, Joaquín Jaén, Carlos López, Maria-Teresa Salvadó, Silvia de Sanjosé.   

Abstract

In lymphoproliferative syndromes, tumoural-immune cell interactions depend on a number of factors related to tumoural and immune cells. Recent gene expression data tend to confirm the decisive role of the reactive microenvironment in the development and clinical behaviour of lymphoproliferative syndromes, and encourage particular interest in the role of T cells and accessory cells. This systematic review brings together the accumulated knowledge about "immune signatures" in Hodgkin and non-Hodgkin lymphomas. Extracted results revealed that the presence of T lymphocytes, regulatory T cells and non-activated CTL in the reactive microenvironment appear commonly to be related with a favourable outcome in the majority of lymphoproliferative syndromes, whereas the presence of TAM, NK cells and activated CTLs appear more usually related with a poor prognosis. The direct involvement of these "immune signatures" in the histopathological morphology, classification, clinicobiological characteristics and outcome of affected patients stimulates the search for new and more appropriate immunotherapeutic strategies.

Entities:  

Mesh:

Year:  2008        PMID: 18996025     DOI: 10.1016/j.critrevonc.2008.09.013

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  6 in total

1.  Clinicobiological, prognostic and therapeutic implications of the tumor microenvironment in follicular lymphoma.

Authors:  Marylène Lejeune; Tomás Alvaro
Journal:  Haematologica       Date:  2009-01       Impact factor: 9.941

2.  Evaluation of significance of lymphocyte subpopulations and non-specific serologic markers in B-cell non-Hodgkin's lymphoma patients.

Authors:  Éva Pósfai; Gábor Irsai; Árpád Illés; Gábor Méhes; Imelda Marton; Csaba Molnár; István Csípő; Sándor Baráth; Lajos Gergely
Journal:  Pathol Oncol Res       Date:  2014-02-01       Impact factor: 3.201

3.  Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro.

Authors:  Camilla A Lindqvist; Lisa H Christiansson; Ingrid Thörn; Sara Mangsbo; Gabriella Paul-Wetterberg; Christer Sundström; Thomas H Tötterman; Bengt Simonsson; Gunilla Enblad; Per Frisk; Ulla Olsson-Strömberg; Angelica S I Loskog
Journal:  Immunology       Date:  2011-04-05       Impact factor: 7.397

4.  Cellular immunotherapy for high-grade glioma.

Authors:  K H Chow; Stephen Gottschalk
Journal:  Immunotherapy       Date:  2011-03       Impact factor: 4.196

Review 5.  Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications.

Authors:  Luis de la Cruz-Merino; Marylène Lejeune; Esteban Nogales Fernández; Fernando Henao Carrasco; Ana Grueso López; Ana Illescas Vacas; Mariano Provencio Pulla; Cristina Callau; Tomás Álvaro
Journal:  Clin Dev Immunol       Date:  2012-08-15

Review 6.  Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes.

Authors:  Tomás Alvaro; Luis de la Cruz-Merino; Fernando Henao-Carrasco; José Luis Villar Rodríguez; David Vicente Baz; Manuel Codes Manuel de Villena; Mariano Provencio
Journal:  J Biomed Biotechnol       Date:  2010-08-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.